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Abstract:
BACKGROUND: To date there are yet no available approved therapies for 
Geographic Atrophy (GA) secondary to age-related macular degeneration 
(AMD). 
METHODS: Single site, non-randomized safety and efficacy study 
presenting the preliminary  results in a cohort of five late stage AMD 
(GA) patients successfully implanted with the Argus II Retinal Prosthesis 
System (Second Sight Medical Products Inc., Sylmar, California, USA). 
Extensive fundus imaging including retinal photographs from which the 
GA area was measured.  A combination of custom and traditional tests 
designed for very low vision subjects assessed visual function in study 
subjects.  A Functional Low-Vision Observer Rated Assessment was 
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carried out to evaluate the impact of the system on the subject’s daily 
life. In addition, a study to evaluate structural characteristics of the 
visual cortex of the brain was performed in one subject using magnetic 
resonance imaging. 
RESULTS: 7 device-related adverse events were reported, 4 of which 
were classed as serious adverse events. Retinal detachment was 
reported in 3 patients and was successfully treated within 12 months of 
onset. Testing showed an improvement in visual function in 3 of 5 
patients with the system turned on. Magnetic resonance imaging 
assessed in one patient after implantation indicates a selective increase 
in cortical myelin and thickness in visual brain regions one year post 
implantation. 
CONCLUSIONS: Epiretinal prostheses can successfully be implanted in 
those affected by GA secondary to late-stage AMD and can elicit visual 
percepts by electrical stimulation of residual neuroretinal elements and 
improve basic visual function in those affected.
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40 BACKGROUND: To date there are yet no available approved therapies for Geographic 
41 Atrophy (GA) secondary to age-related macular degeneration (AMD).
42 METHODS: Single site, non-randomized safety and efficacy study presenting the 
43 preliminary  results in a cohort of five late stage AMD (GA) patients successfully implanted 
44 with the Argus II Retinal Prosthesis System (Second Sight Medical Products Inc., Sylmar, 
45 California, USA). Extensive fundus imaging including retinal photographs from which the 
46 GA area was measured.  A combination of custom and traditional tests designed for very low 
47 vision subjects assessed visual function in study subjects.  A Functional Low-Vision 
48 Observer Rated Assessment was carried out to evaluate the impact of the system on the 
49 subject’s daily life. In addition, a study to evaluate structural characteristics of the visual 
50 cortex of the brain was performed in one subject using magnetic resonance imaging.
51 RESULTS: 7 device-related adverse events were reported, 4 of which were classed as serious 
52 adverse events. Retinal detachment was reported in 3 patients and was successfully treated 
53 within 12 months of onset. Testing showed an improvement in visual function in 3 of 5 
54 patients with the system turned on. Magnetic resonance imaging assessed in one patient after 
55 implantation indicates a selective increase in cortical myelin and thickness in visual brain 
56 regions one year post implantation. 
57 CONCLUSIONS: Epiretinal prostheses can successfully be implanted in those affected by 
58 GA secondary to late-stage AMD and can elicit visual percepts by electrical stimulation of 
59 residual neuroretinal elements and improve basic visual function in those affected.
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61 Almost 1 in 25 people worldwide suffer from severe visual impairment, in the form of 
62 low vision or blindness [1]. In a significant proportion, approximately 10 to 20%, visual 
63 impairment is irreversible. As a result, vision regeneration has recently become the focus of 
64 some exceptional research in an attempt to restore some of the lost vision. Several different 
65 approaches have been investigated to restore sight to those suffering from severe visual 
66 impairment due to retinal or neurological degenerations, including gene therapy and visual 
67 prostheses [2-10]. Age-related Macular Degeneration (AMD) is a disease which describes a 
68 broad designation of signs and symptoms which can significantly impact the retina and 
69 consequent vision. Early and intermediate AMD are characterised by the presence and size of 
70 soft drusen, comprising of lipid deposits at the level of the retinal pigment epithelium (RPE). 
71 Late AMD describes the loss of central vision as a result of damage to the macula and can be 
72 sub-categorised into two forms: Neovascular AMD and Geographic Atrophy (GA). The latter 
73 is characterised by chronic and currently irreversible atrophy affecting the RPE and 
74 photoreceptor cells, resulting in a progressive and devastating loss of vision[11]. It is 
75 estimated that 30-50 million people are affected by AMD globally and this is likely to 
76 increase with the aging population. It is estimated that by 2040 the number affected by late 
77 AMD is set to double, and while those with the Neovascular type can receive treatment in the 
78 form of Anti- Vascular Endothelial Growth Factor (Anti-VEGF), there is no treatment for 
79 those affected by GA currently [12,13].
80 Humayun et al showed that intraocular direct electronic stimulation of atrophic retina 
81 in AMD using a probe during pars plana vitrectomy surgery can elicit visual phosphenes for 
82 the duration of the probe-retina contact [14]. The aim of the retinal prosthesis is to elicit 
83 neural activity in the remaining retinal neurons by detecting light and converting it into 
84 electrical stimuli using artificial devices. As mentioned above, in GA the outer retinal 
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85 structures and photoreceptor cells become depleted whereas inner retinal structures are left 
86 partially intact and therefore can elicit some visual potential [15]. The Argus® II Retinal 
87 Prosthesis System (Second Sight Medical Products Inc., Sylmar, California, USA) is a 
88 commercially available device that aims to restore a basic level of vision to patients with 
89 profound vision loss from outer retinal dystrophies [16]. 
90 Since obtaining a CE mark in 2011 and FDA approval as a humanitarian device in 
91 2013, the device has been predominantly utilised for patients with total loss of vision from 
92 rare genetic diseases such as retinitis pigmentosa (RP) and choroideremia [14,16-24]. AMD 
93 remains one of the leading causes of registered legal severe visual impairment and 
94 irreversible blindness among the elderly in developed parts of the world [25]. Unlike RP or 
95 choroideremia, AMD primarily affects the central retina, which is responsible for high 
96 resolution vision necessary for reading, driving as well as face and object recognition. 
97 Patients do maintain their peripheral vision; however, this does not allow the completion of 
98 the aforementioned tasks. Constant use of peripheral vision is also extremely taxing on the 
99 patient as they are constantly trying to change their angle of vision by moving their heads and 
100 eyes. 
101 Here we describe preliminary safety and efficacy results of five patients with a 




106 The study conformed to World Medical Assembly Declaration of Helsinki 1964 and 
107 subsequent revisions. The study was conducted with compliance to the spirit of Good Clinical 
108 Practice and appropriate approvals were granted from the Human Research Authority (HRA) 
109 and the study was approved by Medicines and Health Products Regulatory Agency (MHRA) 
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110 in the UK and the North West Greater Manchester Research Ethics Committee. The study 
111 was registered on www.clinicaltrials.gov, trial registration number NCT02227498. Written 
112 information was provided to all participants in clear, written form to aid verbal explanations 
113 given by the study team. Audio versions of study documents were also prepared and used 
114 where applicable. Written informed consent was obtained prior to enrolment of each 
115 participant enrolled on to the study.
116 Trial design
117 This is a single arm, non-randomised, controlled feasibility study at a single site. 
118 Potential candidates were screened to ensure they were eligible for the study until the 
119 recruitment target of 5 patients was achieved. The first participant was consented on January 
120 2015 but did not meet the inclusion criteria. The first included participant was consented on 
121 April 2015 and the fifth and last included participant was consented on January 2016. To 
122 date, the follow-up time ranges from 24 to 36 months approximately. Fig 1 shows the 
123 CONSORT flow diagram with further details on screening fails and enrolled participants.
124 Fig 1. CONSORT Flow Diagram. Progress shown through the phases of the trial 
125 (enrolment, intervention allocation, follow-up, and data analysis) up to the first 12 months 
126 reported in the present manuscript.
127 The inclusion criteria were: subjects aged between 25 and 85 years of age who 
128 consented to participate in the study; a diagnosis of late-stage AMD (i.e., evidence of drusen 
129 and hyperplasia of the RPE in the eye with GA secondary to late-stage AMD as determined 
130 by the investigator); severe sight impairment meeting the following additional criteria:
131 • Visual acuity of logMAR 1.0 (6/60) or worse in both eyes as measured by ETDRS;
132 • Hand motion or worse central vision in the eye to be implanted, as measured with a 
133 pinhole occluder;
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134 • GA (confirmed by Fundus Autofluorescence) of at least 18 mm2 extent and central 
135 scotoma (confirmed by microperimetry) in the central 20° or more.
136 • In cases of bilateral GA that meet the study criteria, the eye with worse vision (per 
137 ETDRS VA and microperimetry results) will be chosen for the study procedure.
138 Additionally, subjects had to be pseudophakic with an IOL successfully implanted in 
139 the study eye at least 2 weeks before baseline testing, or aphakic with a clear capsule; 
140 subjects had to be both motivated and competent to learn to use the Argus II System (by the 
141 Investigator's assessment), and willing and able to commit to the study requirements 
142 (including an understanding of the requirements of the study and acceptance of the time 
143 involved in participating). Finally, subjects included in the study must not be suffering from 
144 non-ophthalmic serious adverse events (e.g., myocardial infarction, etc.) or from non-curable 
145 life-threatening conditions (e.g. cancer) at the time of the Baseline visit.
146 Criteria for exclusion of the trial were ocular diseases or conditions that could prevent 
147 the Argus II implant from working (e.g., optic nerve disease, central retinal artery or vein 
148 occlusion, history of retinal detachment, trauma, etc.);; ocular structures or conditions that 
149 could prevent the successful implantation of the Argus II Implant or adequate healing from 
150 surgery (e.g. extremely thin conjunctiva; axial length <20.5 mm or > 26 mm; corneal ulcers; 
151 abnormalities in the typical curvature of the retina like staphyloma and all causes of 
152 significant protrusions or depressions at the macular that could compromise the optimal 
153 position of the electrode array, active or severe blepharitis, evidence of active sub-macular 
154 choroidal neovascularization (CNV) in proposed study eye etc.); ocular diseases or conditions 
155 (other than cataracts) that prevent adequate visualization of the inner structures of the eye 
156 (e.g., corneal opacity). Also excluded from the trial were those subjects with an Implantable 
157 Miniature Telescope in either eye; pre-disposition to eye rubbing or with any disease or 
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158 condition that prevents understanding or communication of informed consent, study 
159 demands, and testing protocols, including:
160 • Cognitive decline including diagnosed forms of dementia and/or progressive 
161 neurologic disease,
162 • Psychiatric disease including diagnosed forms of depression;
163 • Does not speak a principal language associated with the region, and
164 • Deafness or selective frequency hearing loss that prevents hearing device alarms and 
165 alerts.
166 Additional reasons for exclusion were subjects being pregnant or wishing to become 
167 pregnant during the course of the study; participating in another investigational drug or 
168 device study that may conflict with the objectives, follow-up or testing of this study; subjects 
169 with inability to tolerate general anaesthesia or the recommended antibiotic and steroid 
170 regimen associated with the implantation surgery and those subjects with conditions likely to 
171 limit life to less than 1 year from the time of inclusion. 
172 [A full list of inclusion/exclusion criteria is also recorded at www.clinicaltrials.gov, trial 
173 registration number NCT02227498] 
174 While not a specific exclusion criterion, patients with Stargardt’s or other hereditary 
175 macular degenerations were not included in this trial. They were excluded on the basis of not 
176 meeting the primary inclusion criterion of being diagnosed with late-stage AMD (GA). This 
177 determination was made by the investigator after review of the medical history, fundus 
178 imaging, and other screening assessments. 
179 Each of the recruited patients, accompanied by at least one family member, had a 
180 thorough consultation with our research team to understand the nature of this study and set 
181 realistic expectations. All patients gave their written informed consent and the study adhered 
182 to the Declaration of Helsinki. The study was approved by Medicines and Health Products 
Page 9 of 34
https://mc.manuscriptcentral.com/ej-ophthalmology































































183 Regulatory Agency (MHRA) in the UK and the North West Greater Manchester Research 
184 Ethics Committee. Study procedures carried out to ensure eligibility for the study and to 
185 monitor structural and functional changes included the following: optical coherence 
186 tomography (OCT), wide-field retinal fundus photography, fundus autofluorescence and 
187 fluorescein angiography by means of the OPTOS California (Optomap; Optos PLC., 
188 Dunfermline, Scotland, United Kingdom), visual field assessed by the Humphrey Field 
189 Analyzer (HFA; Carl Zeiss Meditec Inc., Dublin, CA), testing with modified visual acuity 
190 (VA) tests for extremely low vision subjects (described elsewhere [17,19,21]) and completion 
191 of the Functional Low-Vision Observer Rated Assessment (FLORA) [26,27]. 
192 Surgery
193 The Argus II System consists of two main components: an extra- and intraocular 
194 portion and an external unit worn by the user (Fig 2).
195 Fig 2. Argus II System. The implant consists of a receiving coil for receiving information 
196 and power from the external components of the Argus II System, an electronics package that 
197 is secured to the outside of the eyeball using a standard scleral band and that drives 
198 stimulation of the electrodes and an electrode array (60 electrodes arranged in a 6 x 10 grid) 
199 that is secured to the surface of the retina by a retinal tack (upper row). The implant receives 
200 power and data commands wirelessly from an external unit. The externals are composed of 
201 the Argus II Glasses and the Argus II Video Processing Unit (VPU) (lower row). A small, 
202 light-weight video camera and a transmitting coil are mounted on a pair of glasses. The 
203 glasses are connected to the VPU via a cable. The VPU is worn by the subject and it converts 
204 the video image captured by the video camera into stimulation commands. The telemetry 
205 coils and radio-frequency system are mounted on the ear piece for transmitting data from the 
206 VPU to the implant. The implant is provided in both left and right eye configurations. The 
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207 device is only implanted in one eye. The study eye was decided according to the requirements 
208 set up in the inclusion criteria. 
209 The extraocular portion of the implant was inserted under the extraocular muscles. 
210 The implant was fixed to the eye via sutures passed through suture tabs on the implant and 
211 secured by a scleral band. In order to insert the intraocular portion implant, core and 
212 peripheral vitrectomies were performed, followed by dissection of any epiretinal membrane 
213 in the area where the electrode array would be placed. The electrode array was then inserted 
214 through an opening in the temporal part of the sclera and secured onto the retina using a 
215 retinal tack. Extensive training and support was provided by the study sponsor for the 
216 surgical staff involved with the study. Professor Stanga had prior experience with the surgical 
217 technique described above from the previous RP study at MREH.  
218 Study assessments 
219 The safety endpoints for this study were the number and nature of adverse events (AEs) in the 
220 implanted subjects. AEs and Serious Adverse Events (SAEs) were documented throughout 
221 the study and included in the data analysis for safety evaluation. 
222 Visual function was assessed for all implanted subjects between both the implanted 
223 and fellow eye, providing data on natural course. Study specific training and certification was 
224 provided by Second Sight to ensure that all involved staff were appropriately trained for their 
225 role on the study. Visual function testing was carried out by specific research optometrists 
226 and assistants named on the study delegation log. ETDRS Visual Acuity (VA), Grating VA, 
227 Square Localisation and Direction of Motion tests comprised the visual function tests.
228 Grating VA, Square Localisation and Direction of Motion tests were custom designed 
229 and provided by Second Sight. Monocular visual acuity (VA) was assessed using ETDRS 
230 Visual Acuity and Grating VA methods with the system turned On/Off in the study eye. 
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231 Traditional methods were used to assess ETDRS VA; central VA measured at 3 meters using 
232 the appropriate 3-meter chart. If a score worse than 1.0 logMAR was obtained the test was 
233 repeated at 1 meter. Grating VA was necessary in those with a visual acuity between 1.6 and 
234 2.9 logMAR.
235 Binocular VA was assessed using Square Localisation and Direction of Motion, assessing 
236 basic visual function in addition to traditional methods of VA assessment. Square 
237 Localisation assessed the subject’s ability to determine light localisation by assessing how 
238 well the subject could distinguish a white square of varying size against a black background. 
239 Direction of Motion assessed motion discrimination by having the subject draw the same 
240 direction of a horizontal line presented to them via a touchscreen monitor.   
241 For visual function assessments the subjects served in three ways as their own control: 
242 comparisons are performed between the system turned ON and OFF, between implanted eyes 
243 and fellow eyes, and between pre‐surgery and post‐surgery performance When results were 
244 compared with the camera ON and OFF and both eyes open, data from a particular subject at 
245 a particular time point was analysed with a two-tailed t-test assuming unequal variances. 
246 Visual function testing was performed at the baseline visit, 3, 6 and 12 months post-op.  
247 A quality of life questionnaire (QOL) was also performed by each patient with the system 
248 turned ON and OFF. The impact of the system on the patients’ daily life was rated by expert 
249 observers in the Functional Low-Vision Observer Rated Assessment (FLORA) QOL 
250 questionnaire. FLORA scores on observed functional vision tasks range from 4 (impossible) 
251 to 1 (easy).
252
253 Cortical changes 
254 An additional research study was carried out in conjunction with the Argus II 
255 feasibility clinical trial to assess the visual cortex of the brain before and after implantation of 
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256 the retinal prosthesis. This part of the study was approved by the NHS Health Research 
257 Authority (IRAS reference 171426; http://www.isrctn.com/ISRCTN52484108) and the York 
258 Neuroimaging Centre Research and Governance Committee. Informed written consent was 
259 obtained from all participants, adhering to the Declaration of Helsinki. Magnetic resonance 
260 imaging (MRI) was used to assess two structural characteristics in the cerebral cortex (grey 
261 matter) of the brain: cortical thickness and cortical myelin levels. Three of the five patients 
262 (patients # 133, # 547 and # 628) were scanned 5-19 days before implantation with the 
263 epiretinal prosthesis. Post-implantation assessments were carried out 13 months following 
264 surgery in patient # 628. Of the remaining two patients scanned pre-implantation, one was 
265 deceased and one withdrew for non-study related reasons. Eight sighted, age-matched control 
266 participants (4 females, mean age 75.1 years, age range 70-83 years) were also scanned under 
267 the same MRI protocol that generated 3D models of the cortical surface [28]. Post-
268 implantation MRI adhered to published safety guidelines on MRI use with the implant device 
269 turned OFF [29]. 
270 Mean cortical thickness and mean cortical myelin levels were measured in three 
271 regions of interest [28] before and after implantation: V1 (primary visual cortex), V2 
272 (secondary visual cortex) and a non-visual control region, OP2, an area in the parietal 
273 operculum that has thickness and myelination levels to visual cortex. 
274
275 Results
276 We successfully recruited 5 eyes with a diagnosis of late-stage AMD (GA) but no 
277 other comorbidity that could affect their vision. Three female and two male patients had the 
278 Argus II System successfully implanted in one eye (i.e. 3 right (OD) and 2 left (OS)). The 
279 mean age of recruited patients was 75 years (±4.6, range: 70.7–79.9). Due to the (non study-
280 related) death of one participant four months after recruitment, surgical results include data 
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281 from 5 participants, but visual function and functional vision results include data from up to 
282 four participants. This study presents the initial results following the first 12 months of the 
283 study, of which continued for a further 4 years approximately. 
284 Surgical and safety results
285 During the implantation surgery there were no complications and surgical results are 
286 considered reproducible across the 5 implanted eyes. All 5 implants were placed over the 
287 centre of the retina (i.e. macula), where structural and functional defects, that is atrophic 
288 retinal areas and central scotomas, were identified and correlated. In 3 of the 5 occasions the 
289 visible atrophic central area was smaller than the retinal area covered or very nearly covered 
290 by the implant electrodes. Adverse Events (AEs) and Serious Adverse Events (SAEs) were 
291 documented throughout the study. During the first 12 months of follow up, we recorded 7 
292 study-related AEs of which 4 were classified as SAEs related to the procedure or device. The 
293 SAEs were: one localised non-rhegmatogenous retinal detachment (RD) under the cable 
294 (Study ID #214), two cases of proliferative vitreoretinopathy (PVR)/retinal detachment 
295 (Study IDs #547, #950, and one case of hypotony (Study ID #628). 
296 All SAEs responded to gas injection or pars plana vitrectomy surgery with silicon oil 
297 and were all resolved within 1 year of onset. One patient also required retinectomy. In 
298 addition, a scleral patch graft was placed in the subject suffering from hypotony to prevent 
299 the leakage around the entry site of the cable.
300 The localized non-rhegmatogenous RD under the cable was observed 1 day after the 
301 implantation surgery and may have been induced during a first unsuccessful attempt of array 
302 insertion into the vitreous cavity. Prior to array insertion there may have been a non-full 
303 thickness choroidal cut at the ends of the 5.2mm incision causing the array to push against the 
304 choroid. After this first unsuccessful attempt of array insertion the surgeon ensured a full-
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305 thickness, full-width choroidal cut with a 15° Stab Knife and Hoskins Forceps. The second 
306 attempt of array insertion was uneventful. The RD was treated with gas injection.
307 The two cases of PVR/retinal detachment with a total tractional retinal detachment in 
308 the 4 quadrants were observed 1.4 months post-implant and 1.9 months post-implant, 
309 respectively. The events were treated with a pars plana vitrectomy, membrane peeling and 
310 silicone oil injection. Both patients reported a loss of peripheral vision in the implanted eye 
311 that recovered after this treatment. In both cases the artificial perception was not affected by 
312 the PVR/retinal detachment.
313 A non-serious and stable macular oedema (MO) was observed in all patients from 
314 approximately 1 month after implantation and during the course of the follow-up (Fig 3). The 
315 macular oedemas were not treated because they did not have any impact on the artificial 
316 perception elicited by the retinal prosthesis.
317 Fig 3. Retinal Fundus and Autofluorescence Images at 1 month. Right eye shown with 
318 large atrophic macular area (upper left) and Left eye shown with a small atrophic area (lower 
319 left). The implant has been placed over the atrophic region. OCT scans from the same eyes 
320 show examples of the Macular Oedemas observed in all eyes.
321 A summary of AEs is given in S1 Table, although further and more specific details on 
322 non-serious AEs are beyond the scope of this report.
323 Electrical Stimulation Results
324 Pre-implantation baseline tests revealed no signs of visual function over the affected 
325 atrophic area of central retina (S1 Fig). Post-implantation, all subjects reported perceiving 
326 phosphenes in response to electrical stimulation from electrodes over the atrophic areas, both 
327 during direct stimulation by the computer, and during stimulation driven by the real-time 
328 video image. Moreover, central visual phosphenes continued to be reported following the 
329 resolution of AEs. 
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330 Active AEs in one of the participants (inability of the patient to attend the protocol 
331 visit and the testing session), and the death of another (unrelated to the implant), resulted in 
332 only three patients participating in visual function assessments. Moreover, missed visits and 
333 errors in the test administration and capture of data resulted in incomplete functional and 
334 structural data collection in the three participants (e.g., missing baseline data in patient #133).
335 In the object localization task, in which the patient was required to locate a white 
336 square on a black touchscreen with both eyes open, one patient (# 133) showed significant 
337 improvement in performance with the system ON compared to OFF at two follow-up visits 
338 (Fig 4), though the mean error was higher than that seen at 3 months for both ON and OFF 
339 conditions.
340 Fig 4. Square Localization and Direction of Motion Results. Individual results of the 
341 performance with system ON (green), system OFF (red) and difference (system OFF- system 
342 ON, blue) for square localization and direction of motion tests over time for three of the 
343 patients. The excluded participant did not have sufficient data to monitor performance over 
344 time due to active AEs. The dotted black line is drawn for reference. Values of the difference 
345 (system OFF- system ON) above the reference line indicate improved performance with 
346 system ON. Axis labels with an asterisk indicate statistically significant differences (p < 0.05) 
347 in performance with the System ON versus OFF.
348 In a visual motion task, in which the patient was asked to draw the direction of motion 
349 of a white line moving across a black screen with both eyes open, performance was 
350 significantly better with the system ON in two of the patients (# 214 and # 950) at one visit 
351 each. The remaining follow up visits and patients, including all assessments of acuity as 
352 measured by Grating Visual Acuity, which is performed monocularly, did not show a 
353 significant difference in performance with the system ON and OFF.
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354 In contrast to artificial, lab-based visual tasks, usage of the system after one year post-
355 implantation for functional vision in a “real world” environment (Fig 5) was also evaluated. 
356 Four subjects participated in the FLORA at baseline and 12 months post-implant. The impact 
357 of the system on the patients’ daily life was rated by expert observers in the FLORA as 
358 positive for one of the participants and as mildly positive for the remaining three. No 
359 instances or reports of double vision, visual confusion, or inability to integrate artificial and 
360 residual vision were reported on the case narratives or in anecdotal reports from the patients 
361 or low vision rehabilitation therapist (data not shown). FLORA scores on observed functional 
362 vision tasks range from 4 (impossible) to 1 (easy). All FLORA domains improved with the 
363 system ON compared to baseline at one year post-implantation, with the greatest 
364 improvement evident in the visual orientation tasks (Fig 5A). However, all visual task 
365 domains increased in difficulty relative to pre-implantation with the system OFF (Fig 5B).
366 Fig 5. Results of the Functional Low-Vision Observer Rated Assessment (FLORA). A) 
367 Rating percentages one year after implant activation for the four participants with the system 
368 OFF (left column) and ON (right column). B) Average FLORA score differences (N = 4) in 
369 two groups (system ON minus OFF at baseline, and System ON minus OFF at 12 months 
370 follow-up, respectively) for the different visual task categories. FLORA scores on observed 
371 functional vision tasks range from 4 (impossible) to 1 (easy). Difference scores above the OX 
372 axis represent better performance with the system ON. Asterisk indicates the only category 
373 where system ON performed worse than pre-implantation (interacting with others tasks).
374 Cortical Changes
375 Three-dimensional models of the cortical surface were generated using structural MRI 
376 data. Fig 6A shows examples of the 3D cortical surface from the patient, providing 
377 qualitative visualisation of cortical thickness and myelin levels across the brain. The three 
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378 regions of interest (ROI) selected for quantitative measurements are also outlined and 
379 labelled – two in visual cortex (V1 and V2) and a third outside of visual cortex (OP2).
380 Quantitative measurements from each ROI are shown in Fig 6B. Prior to implantation 
381 with the retinal prosthesis, mean cortical thickness in V1 and V2 in patient # 628 was below 
382 that of age-matched controls, but had increased 13 months post-implantation, while thickness 
383 in OP2 (the non-visual region) remained close to that of the control group. Cortical 
384 myelination levels in V1 also increased in the patient post-implantation, but remained similar 
385 to controls in V2, while levels in OP2 decreased slightly, but remained above that of controls.
386 Fig 6. Cortical Changes. A) The top two panels are a 3D inflated representation of cerebral 
387 cortex of the brain from patient # 628. Left: lateral view; Right: medial view. The top panel 
388 represents a cortical myelin map; hot colours (red/yellow/green) indicate highly myelinated 
389 areas and colder colours (blue/purple/black) indicate areas with less myelin. The middle 
390 panel represents a cortical thickness map (hot colours indicate brain regions with thicker grey 
391 matter and colder colours indicate brain regions with thinner grey matter). Three regions of 
392 interest representing visual cortex (V1, V2) and a control region (OP2) are outlined in black 
393 and indicated with white text/arrows. B) Quantitative structural brain measures from two 
394 visual regions (V1, V2) and one nonvisual region (OP2). Left panel: Mean cortical thickness; 
395 Right panel: Mean cortical myelin levels. Data shown in red is from patient # 628, pre-
396 surgery, blue bars represent data from the patient post-surgery, and green bars represent 
397 averages from a group of age-matched sighted controls (N=8).
398
399 Discussion
400 This study tested for the first time ever the hypothesis that an electronic epiretinal 
401 prosthesis may restore functional vision for patients diagnosed with advanced macular 
402 geographic atrophy in late-stage AMD, offering artificial vision in the defective central area 
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403 of their visual field. This manuscript includes safety and efficacy outcomes and neuro-
404 structural assessments up to the first 12 months after implantation. The reported results show 
405 that surgical implantation of an electronic epiretinal prosthesis system is possible in patients 
406 with advanced GA, secondary to Late AMD.    The results also show that the implant can 
407 elicit visual percepts in areas of GA in late AMD patients. Although it is important to take 
408 into consideration that our small sample of patients does not allow for a strong statistical 
409 interpretation of the structural and functional assessments pre- and post- operatively, study 
410 outcomes strengthen our hypothesis that an epiretinal prosthesis approach may be beneficial 
411 for this cohort of patients.
412 In this study we observed 3 retinal detachments (one localised non-rhegmatogenous 
413 retinal detachment under the cable and two cases of proliferative vitreoretinopathy/retinal 
414 detachment; 3 out of 5 subjects experienced RD) and it represents the major SAE. The 
415 percentage of clinical trial subjects with RP implanted with the Argus II Retinal Prosthesis 
416 System that experienced RD was 6.7% at 1 year after implantation [16], 6.7% at 3 years [21] 
417 and 10.0% at 5 years [30]. The non-rhegmatogenous retinal detachment under the cable 
418 observed at post-operative day1 was most probably due to the surgical step of forcing the 
419 electrode array through a shorter sclerotomy incision against resistance during the array 
420 insertion into the vitreous cavity. To reduce the likelihood of such complication, during the 
421 sclerotomy incision, a full-thickness, full-width choroidal cut throughout the entire length of 
422 the 5.2mm incision should be made. The root causes of the two cases of proliferative 
423 vitreoretinopathy/retinal detachment are unclear. A hypothesis could be that PVR/retinal 
424 detachment is due to “chronic chorio-retinal inflammation and/or foreign body reaction”  as it 
425 has been reported when retinal tacks were initially used for the treatment of retinal 
426 detachment [31]. Another hypothesis could be that PVR can originate from the large and 
427 traumatic 5.2mm pars-plana incision due to the migration and proliferation of retinal pigment 
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428 epithelium (RPE) cells. In fact, PVR-related total retinal detachment was also observed when 
429 performing excision with translocation of RPE/Bruch's Membrane from the paramacular area 
430 to the subfoveal space during the treatment of AMD [32]. PVR may also develop from 
431 vitreous residuals or from hyaloid residuals that go into hyper-proliferation. The Argus II 
432 Surgeon Manual recommends performing the vitrectomy after the extraocular placement of 
433 the device. This may hinder meticulous removal of minute amounts of vitreous and hyaloid 
434 membrane because of the presence of the implant around the eye. Accurate removal of 
435 peripheral vitreous with scleral depressed vitrectomy is limited by the presence of the 
436 electronics case and the implant coil in the supero-temporal and infero-temporal quadrants.
437 Vitrectomy may be performed at the beginning of the procedure and before the 
438 extraocular placement of the device. Adjuvant combination therapy in the vitrectomy infusion 
439 using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of 
440 PVR may also be considered [33].
441 While serious, the device-related adverse events described above have limited 
442 impact on vision in these patients. Baseline visual function was primarily affected by their  
443 late-stage AMD and central area of GA prior to implantation, given the level of sight 
444 impairment caused.Visual function was mainly assessed through three custom-developed 
445 computer-based psychophysical tests with the purpose of specifically assessing a range of 
446 low vision as that restored by the retinal implant. These same tests were developed for and 
447 have been used in a cohort of patients diagnosed with RP and implanted with the Argus II 
448 system [30]. However, visual acuity outcomes are not comparable between studies, due to the 
449 persistent and varied visual benefit from this cohort’s peripheral residual vision, an element 
450 that RP patients lack. The authors believe that the design and implementation of these visual 
451 function tests should be further tailored to the needs of GA-AMD patients so that more robust 
452 conclusions can be drawn in the future regarding the integration of both the natural peripheral 
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453 vision and the artificial central vision provided by the system. Nevertheless, based on the data 
454 obtained so far, it seems possible that a retinal implant could be beneficial to restore some 
455 visual function for future late stage AMD (GA) patients. 
456 When FLORA is performed, patients serve as their own control as results are 
457 evaluated both with the system ON and OFF. However, it should be pointed out that this is a 
458 subjective evaluator-reported assessment and neither the evaluator nor the patient was 
459 masked to the operational status of the device when completing the tasks. FLORA outcomes 
460 at 12 months after implantation from this study are in good agreement with those found in 
461 another published multicentre study (in RP patients) [27]. Our results agree with those of 
462 Geruschat et al. in that those tasks related to the use of the system in conditions of maximum 
463 light contrast such as the visual orientation tasks, appeared to benefit most from usage of the 
464 system [27]. In the present study, performance in tasks involving mobility and interaction 
465 with others also improved with the system. Such tasks may enhance patient independence and 
466 social interaction. Subjects’ improved ability to perform functional vision tasks with the 
467 System ON compared to OFF suggests that some integration of artificial central vision and 
468 natural peripheral vision may occur; the absence of reported monocular double vision or 
469 confusion in the implanted eye is further evidence that stimulation from the implant is not 
470 detrimental to these patients.
471 MRI assessments of the brain pre- and post-implantation evaluated the impact of 
472 vision restoration through use of the implant device on the visual cortex. Previous research 
473 reports that long-term visual deprivation from AMD results in reduced grey and white matter 
474 [34-36]. MRI could therefore identify whether the Argus II device could potentially prevent 
475 further cortical reductions or even reverse them by restoring visual input to the brain.
476 Statistical analysis could not be performed, as only one patient (# 628) completed 
477 MRI both pre- and post-implantation. Nevertheless, data for this patient showed an increase 
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478 in cortical thickness following 13 months’ use of the device from baseline. This increase was 
479 observed in both primary visual cortex (V1), the first cortical region in the brain that receives 
480 visual inputs, and in secondary visual cortex (V2), and associative visual area. However, no 
481 increase in thickness was observed in a control region of the brain not associated with visual 
482 processing (OP2). Therefore, the lack of change observed here could indicate that increases 
483 in visual cortex are due to use of the Argus II device, but such a conclusion cannot be made 
484 without conducting a large-scale study. 
485 Areas with high cortical myelin levels are usually primary sensory or motor in 
486 function, reflecting a large proportion of inputs or outputs. In this study, we observed an 
487 increase in cortical myelin in the patient in V1 13 months post-implantation, possibly as a 
488 result of the restoration of visual input signals from the system. No change was observed in 
489 cortical myelin in V2 post-treatment; it is possible such changes might take longer to 
490 develop. Whether these reported changes correspond retinotopically to the macula in the 
491 implanted eye or to the contralateral eye is yet to be determined. However, the fact that 
492 changes were significant enough to affect mean thickness and myelin throughout visual 
493 cortex suggests the implant may have a positive effect overall.
494 In summary, the recruitment of five patients with GA-AMD and their implantation 
495 with an electronic epiretinal implant has offered a plethora of information over the first 12 
496 months and potentially opens doors to more research in this area and future clinical 
497 indications for artificial vision. Invaluable data is still being collected from four of those 
498 patients giving a great opportunity to the research community to assess whether a retinal 
499 prosthesis is a feasible approach for the treatment of GA-AMD, one of the most common eye 
500 pathologies responsible for severe visual impairment. The system has proven to be safe and 
501 favourable in patients with total vision loss from RP and choroideremia. However, the current 
502 implant design, which has gained regulatory approval for implantation in patients with severe 
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503 outer retinal degeneration and has proven to be beneficial for the above cohort, does not have 
504 the same quality of life changing effect on patients with GA secondary to late stage AMD. 
505 Nevertheless, we have here shown for the first time ever that an electronic epiretinal 
506 implant can elicit visual percepts by electrical stimulation of residual neuroretinal elements 
507 over the atrophic macula that can be incorporated by patients into their residual vision with 
508 no visual adverse effects such as monocular confusion or double vision. 
509 It was previously thought that it would be impossible to elicit visual function in 
510 atrophic retinal areas with no functional response to focal stimulation by a light stimulus. 
511 However, as a result of this study, we strongly believe that further research in this area is now 
512 justified and that different approaches in the design of retinal implants themselves (e.g. 
513 smaller implant size, larger number of electrodes, redesign of the tack to prevent excessive 
514 mechanical forces) and in the image processing software and settings could benefit potential 
515 future research candidates. 
516 Post 1-year functional results and AEs will be reported in a separate publication.
517 This is the First-in-Human use of artificial vision in patients with residual peripheral vision as 
518 well as the first implantation of an electronic retinal prosthesis in GA-AMD. We also show, 
519 for the first time, Proof of Concept that an electronic retinal prosthesis can elicit visual 




524 PE Stanga left the National Health System (NHS), the Manchester Royal Eye Hospital and the 
525 University of Manchester in 2019 and continues his Clinical, Surgical and R&D activities at 
526 London Vision Clinic, with which he partnered in 2017.
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527 Some of the data reported in this manuscript have been presented in scientific 
528 ophthalmological meetings, such as the Association of Research for Vision and 
529 Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO) and 
530 EURETINA. 
531 The study was sponsored by Second Sight Medical Products Inc., Sylmar, California, 
532 USA and was undertaken at the Manchester Vision Regeneration (MVR) Lab at the 
533 Wellcome Trust Clinical Research Facility and Manchester Royal Eye Hospital, Manchester 
534 Foundation Trust. Principal Study Investigator and Surgeon is Prof Paulo E Stanga, also 
535 director of the MVR Lab. Prof. Stanga is no longer part of the above and currently conducts 
536 his clinical, surgical and resea ch activities at the London Vision Clinic, where he is Retina 
537 Lead, Principal Investigator and Partner.
538  Apart from the aforementioned authors Emmanouil Tsamis, Irene Siso-Fuertes and 
539 Fiona Crawford, the MVR Lab Group also consisted of Research Fellows and Clinical Trial 
540 Coordinators who assisted Prof Stanga during this study. These are: Sherif Shaarawy – 
541 Clinical Research Fellow, Soon Ch’ng – Clinical Research Fellow, Alessandro Papayannis – 
542 Clinical Research Fellow, Katarzyna Chwierjzack – Clinical Research Fellow, Francesco 
543 Stringa – Clinical Research Fellow, Salvador Pastor-Idoate – Clinical Research Fellow, 
544 Danielle Marrochia – Clinical Trial Coordinator, Niall Doherty – Clinical Trial Coordinator. 
545 Prof Stanga would like to thank them for their invaluable assistance during this study course.
546 The MVR Lab (closed down following the departure of P.E. Stanga) Group would 
547 also like to thank the Imaging Department of Manchester Royal Eye Hospital, and Mr Assad 
548 Jalil, Consultant, for their help. Also, special thanks should go to Mr Susmito Biswas, 
549 Clinical Head of Division, Manchester Royal Eye Hospital, for his support. Further thanks 
550 are extended to the York Neuroimaging Centre and its staff for assisting with MRI 
551 acquisition.
Page 24 of 34
https://mc.manuscriptcentral.com/ej-ophthalmology


































































555 1. Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. British Journal of 
556 Ophthalmology 96: 614-618.
557 2. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, et al. (2001) Gene therapy restores vision in a 
558 canine model of childhood blindness. Nature Genetics 28: 92-95.
559 3. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy 
560 on visual function in Leber's congenital amaurosis. New England Journal of Medicine 358: 
561 2231-2239.
562 4. Brandli A, Luu CD, Guymer RH, Ayton LN (2016) Progress in the clinical development and 
563 utilization of vision prostheses: an update. Eye Brain 8: 15-25.
564 5. Damle S, Lo YH, Freeman WR (2017) High Visual Acuity Retinal Prosthesis: Understanding 
565 Limitations and Advancements Toward Functional Prosthetic Vision. Retina.
566 6. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, et al. (2008) Treatment of Leber 
567 congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-
568 associated virus gene vector: Short-term results of a phase I trial. Human Gene Therapy 19: 
569 979-990.
570 7. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, et al. (2012) Gene therapy for 
571 leber congenital amaurosis caused by RPE65 mutations: Safety and efficacy in 15 children 
572 and adults followed up to 3 years. Archives of Ophthalmology 130: 9-24.
573 8. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, et al. (2014) Retinal gene therapy 
574 in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial. The Lancet 
575 383: 1129-1137.
576 9. Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, et al. (2008) Safety and efficacy of 
577 gene transfer for Leber's congenital amaurosis. New England Journal of Medicine 358: 2240-
578 2248.
579 10. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, et al. (2010) Gene therapy for leber's 
580 congenital amaurosis is safe and effective through 1.5 years after vector administration. 
581 Molecular Therapy 18: 643-650.
582 11. Ferris FL, III, Wilkinson CP, Bird A, Chakravarthy U, Chew E, et al. (2013) Clinical Classification of 
583 Age-related Macular Degeneration. Ophthalmology 120: 844-851.
584 12. Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, et al. (2017) Prevalence of Age-
585 Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology 124: 
586 1753-1763.
587 13. Wong WL, Su X, Li X, Cheung CM, Klein R, et al. (2014) Global prevalence of age-related macular 
588 degeneration and disease burden projection for 2020 and 2040: a systematic review and 
589 meta-analysis. Lancet Glob Health 2: e106-116.
590 14. Humayun MS, de Juan E, Jr., Dagnelie G, Greenberg RJ, Propst RH, et al. (1996) Visual perception 
591 elicited by electrical stimulation of retina in blind humans. Arch Ophthalmol 114: 40-46.
592 15. Li M, Huisingh C, Messinger J, Dolz-Marco R, Ferrara D, et al. (2018) HISTOLOGY OF GEOGRAPHIC 
593 ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Multilayer Approach. 
594 Retina 38: 1937-1953.
595 16. Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, et al. (2012) Interim results from the 
596 international trial of Second Sight's visual prosthesis. Ophthalmology 119: 779-788.
Page 25 of 34
https://mc.manuscriptcentral.com/ej-ophthalmology































































597 17. Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, et al. (2011) Blind subjects implanted with 
598 the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J 
599 Ophthalmol 95: 539-543.
600 18. da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, et al. (2013) The Argus II epiretinal prosthesis 
601 system allows letter and word reading and long-term function in patients with profound 
602 vision loss. Br J Ophthalmol 97: 632-636.
603 19. Dorn JD, Ahuja AK, Caspi A, da Cruz L, Dagnelie G, et al. (2013) The Detection of Motion by Blind 
604 Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis. JAMA Ophthalmol 
605 131: 183-189.
606 20. FDA Humanitarian Device Exemption (HDE).
607 21. Ho AC, Humayun MS, Dorn JD, da Cruz L, Dagnelie G, et al. (2015) Long-Term Results from an 
608 Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology 122: 1547-1554.
609 22. Humayun MS, Dorn JD, Ahuja AK, Caspi A, Filley E, et al. (2009) Preliminary 6 month results from 
610 the Argus II epiretinal prosthesis feasibility study. Conf Proc IEEE Eng Med Biol Soc 2009: 
611 4566-4568.
612 23. Rizzo S, Belting C, Cinelli L, Allegrini L, Genovesi-Ebert F, et al. (2014) The Argus II Retinal 
613 Prosthesis: 12-month outcomes from a single-study center. Am J Ophthalmol 157: 1282-
614 1290.
615 24. Stronks HC, Dagnelie G (2014) The functional performance of the Argus II retinal prosthesis. 
616 Expert Rev Med Devices 11: 23-30.
617 25. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual 
618 impairment in the year 2002. Bulletin of the World Health Organization 82: 844-851.
619 26. Geruschat DR, Flax M, Tanna N, Bianchi M, Fisher A, et al. (2015) FLORA: Phase I development of 
620 a functional vision assessment for prosthetic vision users. Clin Exp Optom 98: 342-347.
621 27. Geruschat DR, Richards TP, Arditi A, da Cruz L, Dagnelie G, et al. (2016) An analysis of observer-
622 rated functional vision in patients implanted with the Argus II Retinal Prosthesis System at 
623 three years. Clin Exp Optom 99: 227-232.
624 28. Glasser MF, Sotiropoulos SN, Wilson JA, Coalson TS, Fischl B, et al. (2013) The minimal 
625 preprocessing pipelines for the Human Connectome Project. Neuroimage 80: 105-124.
626 29. Weiland JD, Faraji B, Greenberg RJ, Humayun MS, Shellock FG (2012) Assessment of MRI issues 
627 for the Argus II retinal prosthesis. Magn Reson Imaging 30: 382-389.
628 30. da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, et al. (2016) Five-Year Safety and 
629 Performance Results from the Argus II Retinal Prosthesis System Clinical Trial. 
630 Ophthalmology 123: 2248-2254.
631 31. de Juan E, Jr., Hickingbotham D, Machemer R (1985) Retinal tacks. Am J Ophthalmol 99: 272-274.
632 32. Stanga PE, Kychenthal A, Fitzke FW, Halfyard AS, Chan R, et al. (2001) Retinal pigment epithelium 
633 translocation and central visual function in age related macular degeneration: preliminary 
634 results. Int Ophthalmol 23: 297-307.
635 33. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, et al. (2001) Adjuvant 5-fluorouracil and 
636 heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, 
637 controlled clinical trial. Ophthalmology 108: 1179-1183.
638 34. Boucard CC, Hernowo AT, Maguire RP, Jansonius NM, Roerdink JB, et al. (2009) Changes in 
639 cortical grey matter density associated with long-standing retinal visual field defects. Brain 
640 132: 1898-1906.
641 35. Hernowo AT, Prins D, Baseler HA, Plank T, Gouws AD, et al. (2014) Morphometric analyses of the 
642 visual pathways in macular degeneration. Cortex 56: 99-110.
643 36. Malania M, Konrad J, Jagle H, Werner JS, Greenlee MW (2017) Compromised Integrity of Central 
644 Visual Pathways in Patients With Macular Degeneration. Invest Ophthalmol Vis Sci 58: 2939-
645 2947.
646
Page 26 of 34
https://mc.manuscriptcentral.com/ej-ophthalmology
































































648 Supporting information captions
649 S1 Fig. Fundus Photographs, OCT, and Microperimetry Results. 
650 S1 Table. Summary of Adverse Events (AEs).
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CONSORT 2010 Flow Diagram
**Please note this was a single arm, non-randomised, controlled feasibility study**
Assessed for eligibility (n=  )
Excluded  (n=   )
   Not meeting inclusion criteria (n=  )
   Declined to participate (n=  )
   Other reasons (n=  )
Analysed  (n=  )
 Excluded from analysis (give reasons) (n=  )
Lost to follow-up (give reasons) (n=  )
Discontinued intervention (give reasons) (n=  )
Allocated to intervention (n=  )
 Received allocated intervention (n=  )
 Did not receive allocated intervention (give 
reasons) (n=  )
Lost to follow-up (give reasons) (n=  )
Discontinued intervention (give reasons) (n=  )
Allocated to intervention (n=  )
 Received allocated intervention (n=  )
 Did not receive allocated intervention (give 
reasons) (n=  )
Analysed  (n=  )




Randomized (n=  )
Enrollment
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